Bill
Bill > A2795
NJ A2795
NJ A2795Expands requirements for health insurance carriers concerning prostate cancer screening and requires coverage be provided without cost sharing.
summary
Introduced
02/28/2022
02/28/2022
In Committee
02/28/2022
02/28/2022
Crossed Over
Passed
Dead
01/08/2024
01/08/2024
Introduced Session
2022-2023 Regular Session
Bill Summary
This bill requires health, hospital, and medical service corporations, health maintenance organizations, and commercial group health insurers to provide coverage for an annual prostate cancer screening without cost sharing. Under current law, these health insurance carriers are required only to provide coverage for an annual medically recognized diagnostic examination including, but not limited to, a digital rectal examination and a prostate-specific antigen test for men age 50 and over who are asymptomatic and for men age 40 and over with a family history of prostate cancer or other prostate cancer risk factors. The bill expands the definition of "prostate cancer screening" to mean medically viable methods for the detection and diagnosis of prostate cancer, which includes a digital rectal exam and the prostate-specific antigen test and associated laboratory work. "Prostate cancer screening" shall also include subsequent follow up testing as direct by a physician, including, but not limited to: (1) urinary analysis; (2) serum biomarkers; (3) medical imaging, including, but not limited to, magnetic resonance imaging. The bill also extends the prostate cancer screening requirements to commercial individual health insurers, health benefits plans issued pursuant to the New Jersey Individual Health Coverage and Small Employer Health Benefits Programs, the State Health Benefits Program, and the School Employees' Health Benefits Program, which are not required to provide this coverage under current law.
AI Summary
This bill requires health, hospital, and medical service corporations, health maintenance organizations, and commercial group, individual, and small employer health insurers to provide coverage for an annual prostate cancer screening without any cost-sharing requirements. The bill expands the definition of "prostate cancer screening" to include various medically viable methods for the detection and diagnosis of prostate cancer, including digital rectal exams, prostate-specific antigen (PSA) tests, and associated follow-up testing such as urinalysis, serum biomarkers, and medical imaging. The bill also extends these prostate cancer screening coverage requirements to the State Health Benefits Program and the School Employees' Health Benefits Program.
Committee Categories
Business and Industry
Sponsors (6)
Daniel Benson (D)*,
Herbert Conaway (D)*,
Joe Danielsen (D)*,
Antwan McClellan (R),
Raj Mukherji (D),
Erik Simonsen (R),
Last Action
Introduced, Referred to Assembly Financial Institutions and Insurance Committee (on 02/28/2022)
Official Document
bill text
bill summary
Loading...
bill summary
Loading...
bill summary
| Document Type | Source Location |
|---|---|
| State Bill Page | https://www.njleg.state.nj.us/bill-search/2022/A2795 |
| BillText | https://pub.njleg.gov/Bills/2022/A3000/2795_I1.HTM |
| Bill | https://pub.njleg.gov/Bills/2022/A3000/2795_I1.PDF |
| BillText | https://www.njleg.state.nj.us/Bills/2022/A3000/2795_I1.HTM |
| Bill | https://www.njleg.state.nj.us/Bills/2022/A3000/2795_I1.PDF |
Loading...